The company's integrated model accelerates its ability to deliver lower cost of care, a simpler experience and better outcomes. In addition, the expansion of both the margins in the quarter was highly encouraging. The company's innovation is accelerating more transparent pharmacy reimbursement models, increasing the use of biosimilars and improving patient outcomes through its connected healthcare delivery assets.Management is currently looking to capitalize on opportunities, including earlier leadership changes in the Health Care Benefits segment.(Read more: CVS Health Q3 Earnings & Revenues Beat)Thanks to several business-specific and industry-wide factors, the market has not been impressed with the company this year. Year to date, CVS Health witnessed a 29.3% decline against the S&P 500's climb of 2.1%.